Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 93

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 93
---
 the degree and nature of the stimulation, which enables the multiple potential product candidates in development. Figure 1: Interaction of PHAD with TLR4 57 Gemini-AKI The Gemini -AKIprogram is being developed as a potential therapy for the prevention of AKI due to external stress or insult (e.g. surgical procedure, chemotherapy toxicity). We believe immunologic preconditioning with Gemini prepares the body to handle biologic stress by redirecting the body’s immune system to have an attenuated response to the stress. Preclinical studies have demonstrated that preconditioning with PHAD significantly reduces the severity and duration of AKI following an ischemia of the kidney. Additional data from these preclinical studies have been accepted for presentation at The International Conference on Advances in Critical Care Nephrology on March 12, 2024. During 2024 we conducted a Phase 1 clinical study. safety and biomarker activity data from our Phase 1 clinical study was announced in June of 2024, showing a significant increase in anti -inflammatorycytokines including IL -1RAand IL -10. In January of 2025 we announced the start of our Phase 1b clinical study in CKD patients. The Phase 1b clinical study will support further development of Gemini -AKI. We expect data from our Phase 1b clinic study in the first half of this year. Gemini-CKD The Gemini -CKDprogram is being developed as a potential therapy for preventing the progression of CKD. We believe Gemini may modulate the immune response from a pro -inflammatorystate to an anti -inflammatory(protective) state to rebalance the innate immune response and slow down or halt the progressive destruction and scarring of organ tissue, allowing the healing process to take place. Preclinical studies have demonstrated that Gemini significantly reduces the degree of scar tissue formation in a hyperinflammatory kidney injury model. In January of 2025 we announced the start of our Phase 1b clinical study in CKD patients. The Phase 1b clinical study will support further development of Gemini -CKD. We expect data from our Phase 1b clinic study in the first half of this year. Gemini-PSI The Gemini -PSIprogram is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention or treatment of surgical site infection. We believe immunologic preconditioning with Gemini prepares the body to resist infection by priming the body’s immune system to better and more rapidly respond